KELADA PHARMACHEM LIMITED

Their core work

Kelada Pharmachem is an Irish SME specializing in pharmaceutical chemistry, with particular strength in developing greener, more efficient chemical processes for drug manufacturing. They focus on areas such as chemo-enzymatic synthesis, organocatalysis, halogenation chemistry, and fluorine-based methods applied to drug discovery. More recently, they have expanded into RNA-protein interaction analysis using mass spectrometry and proteomics. Their consistent participation in MSCA-RISE staff exchange projects indicates a business model built around international knowledge transfer and collaborative R&D with academic partners.

What they specialise in

How they've shifted over time

Kelada's early H2020 work (2015–2018) centered on process chemistry for drug manufacturing — chemo-enzymatic routes and quaternary ammonium salts as pharmaceutical intermediates. From 2019 onward, their focus sharpened toward green chemistry methods (organocatalysis, continuous flow) and expanded into a new domain: RNA biology and proteomics. This shift from pure process chemistry toward biological target characterization suggests the company is broadening from manufacturing-side chemistry into earlier-stage drug discovery tools.

Kelada is moving upstream from pharmaceutical process chemistry into drug discovery tools, particularly fluorine-based methods and RNA-protein interaction platforms — positioning them at the intersection of chemistry and biology.

How they like to work

Kelada operates primarily as a participant in small MSCA-RISE consortia, joining 3 of 4 projects as a partner before stepping up to coordinate ProteRNA in 2021. With only 7 unique consortium partners across 6 countries, they work in tight, focused teams rather than large consortia. Their progression to coordinator status suggests growing confidence and leadership capacity within their niche.

Kelada has built a compact but internationally diverse network of 7 partners across 6 countries, consistent with MSCA-RISE staff exchange projects that prioritize cross-border researcher mobility. Their network likely spans academic chemistry and pharmacy departments across Europe.

What sets them apart

Kelada occupies an unusual niche as an Irish pharmaceutical chemistry SME that bridges academic research and industrial application through staff exchange programs. Their combination of green chemistry process expertise with emerging capabilities in RNA-protein biology is distinctive — few small companies span both synthetic chemistry and proteomics. For consortium builders, they offer an industry partner with hands-on pharmaceutical chemistry experience who is accustomed to researcher mobility and knowledge transfer frameworks.

Highlights from their portfolio

• ProteRNA
  Their first project as coordinator, and a significant pivot into RNA-protein interaction biology — signaling a strategic expansion beyond traditional pharmaceutical chemistry.
• GreenX4Drug
  Their largest funded project (EUR 220,800), combining organocatalysis, green chemistry, and continuous flow methods for drug manufacture — their most technically detailed contribution.